2. Academic Validation
  3. Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide

Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide

  • Eur J Med Chem. 2014 Feb 12:73:46-55. doi: 10.1016/j.ejmech.2013.11.044.
Hongtao Xu 1,  Huanyu Tang 1,  Huijin Feng 1,  Yuanchao Li 2
Affiliations

Affiliations

  • 1 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, PR China.
  • 2 Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, PR China. Electronic address: ycli@mail.shcnc.ac.cn.
PMID: 24378709 DOI: 10.1016/j.ejmech.2013.11.044
Abstract

Two series of novel C14 heterocycle substituted epi-triptolide derivatives as potential Anticancer agents were synthesized and tested for their cytotoxicity against SKOV-3 and PC-3 tumor cell lines. The introduction of C14β-aryl heterocycle aminomethyl substituent to the leading compound was found to be an effective modification method to retain the potent Anticancer activity. Meanwhile, the series of epi-triptolide derivatives (21-40) with C14α-hydroxyl group, still retained the natural product's cytotoxicity. This is apparently challenges the classical structure-activity relationship of triptolide that considers the C14β-hydroxyl group to be essential for its Anticancer activity.

Keywords

Anticancer; Heterocycle; PC-3; SKOV-3; Synthesis; Triptolide.

Figures